20:37 , Feb 2, 2018 |  BC Week In Review  |  Clinical News

Takeda, Zinfandel's AD test fails to deliver

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and partner Zinfandel Pharmaceuticals Inc. (Durham, N.C.) discontinued the Phase III TOMMORROW trial of 0.8 mg pioglitazone (AD-4833) after a planned interim futility analysis showed that the compound was inadequate...
22:51 , Jan 25, 2018 |  BC Extra  |  Clinical News

Takeda, Zinfandel’s AD test fails to deliver

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and partner Zinfandel Pharmaceuticals Inc. (Durham, N.C.) discontinued the Phase III TOMORROW trial of 0.8 mg pioglitazone (AD-4833) SR after an interim futility analysis showed the compound was inadequate in...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Clinical News

Actos pioglitazone: Completed Phase III enrollment

Takeda and Zinfandel (Chapel Hill, N.C.) completed enrollment of about 3,500 patients ages 65-83 in the double-blind, placebo-controlled, international Phase III TOMMORROW trial evaluating 0.8 mg oral AD-4833 once daily for up to 5 years....
07:00 , Sep 16, 2013 |  BC Week In Review  |  Clinical News

Biomarker risk assignment algorithm: Phase III started

Takeda and Zinfandel began the double-blind, international Phase III TOMMORROW trial of oral AD-4833 once daily for up to 5 years and the biomarker risk assignment algorithm in about 5,800 cognitively normal subjects ages 65-83....
07:00 , Sep 16, 2013 |  BC Week In Review  |  Clinical News

Actos pioglitazone: Phase III started

Takeda and Zinfandel Pharmaceuticals Inc. (Durham, N.C.) began the double-blind, international Phase III TOMMORROW trial of oral AD-4833 once daily for up to 5 years and the biomarker risk assignment algorithm in about 5,800 cognitively...
07:00 , Aug 5, 2013 |  BC Week In Review  |  Clinical News

Biomarker risk assignment algorithm diagnostic data

An analysis of 660 patients enrolled in the Alzheimer's Disease Neuroimaging Initiative (ADNI) showed that Takeda's biomarker risk assignment algorithm for predicting onset of MCI due to late-onset AD had a PPV of 79% and...